- Home
- PSF vs BWAY Comparison
PSF vs BWAY Comparison
Compare PSF & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- BWAY
- Stock Information
- Founded
- PSF 2010
- BWAY 2003
- Country
- PSF United States
- BWAY Israel
- Employees
- PSF N/A
- BWAY N/A
- Industry
- PSF Investment Managers
- BWAY Medical/Dental Instruments
- Sector
- PSF Finance
- BWAY Health Care
- Exchange
- PSF Nasdaq
- BWAY Nasdaq
- Market Cap
- PSF 244.9M
- BWAY 207.4M
- IPO Year
- PSF N/A
- BWAY 2019
- Fundamental
- Price
- PSF $20.30
- BWAY $10.75
- Analyst Decision
- PSF
- BWAY Strong Buy
- Analyst Count
- PSF 0
- BWAY 3
- Target Price
- PSF N/A
- BWAY $13.17
- AVG Volume (30 Days)
- PSF 25.0K
- BWAY 72.3K
- Earning Date
- PSF 01-01-0001
- BWAY 03-05-2025
- Dividend Yield
- PSF 7.69%
- BWAY N/A
- EPS Growth
- PSF N/A
- BWAY N/A
- EPS
- PSF N/A
- BWAY 0.04
- Revenue
- PSF N/A
- BWAY $38,631,000.00
- Revenue This Year
- PSF N/A
- BWAY $388.82
- Revenue Next Year
- PSF N/A
- BWAY $18.70
- P/E Ratio
- PSF N/A
- BWAY $143.24
- Revenue Growth
- PSF N/A
- BWAY 34.19
- 52 Week Low
- PSF $16.00
- BWAY $4.61
- 52 Week High
- PSF $20.19
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- PSF 54.11
- BWAY 51.17
- Support Level
- PSF $20.28
- BWAY $10.33
- Resistance Level
- PSF $20.45
- BWAY $11.79
- Average True Range (ATR)
- PSF 0.13
- BWAY 0.56
- MACD
- PSF -0.01
- BWAY 0.01
- Stochastic Oscillator
- PSF 57.14
- BWAY 46.39
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.